Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Fluoride-18 Anion
2. 18f-fluoride
3. (18f)-fluoride
4. Fluorine-18(1-)
5. 67862-54-8
6. 4m4we5n2ge
7. Unii-4m4we5n2ge
8. Fluoride-18f
9. Fluoride-18
10. Fluoride F-18
11. Fluoride Ion F 18
12. Fluoride Ion, F-18
13. Fluoride (18f1-)
14. Fluorine-18 Ion(1-)
15. Dtxsid80218101
16. Db09398
17. Q27260079
| Molecular Weight | 18.000937 g/mol |
|---|---|
| Molecular Formula | F- |
| XLogP3 | 0.6 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 1 |
| Rotatable Bond Count | 0 |
| Exact Mass | 18.000937 g/mol |
| Monoisotopic Mass | 18.000937 g/mol |
| Topological Polar Surface Area | 0 Ų |
| Heavy Atom Count | 1 |
| Formal Charge | -1 |
| Complexity | 0 |
| Isotope Atom Count | 1 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
18F is used as a bone imaging agent to define areas of altered osteogenic activity. It has been indicated for back pain and otherwise unexplained bone pain, child abuse, abnormal radiographic or laboratory findings, osteomyelitis, trauma, inflammatory and degenerative arthritis, avascular necrosis. Osteonecrosis of the mandible, condylar hyperplasia, and metabolic bone disease are also among the indications for fluoride imaging.
Deposition of 18F fluoride in bone appears to be primarily a function of blood flow to the bone and the efficiency of the bone in extracting the 18F from the blood perfusing the bone. Increased fluorine F 18 ion deposition around joints can occur in arthritis or following trauma; increased deposition has also been documented in bone around fracture sites, in osteomyelities, fibrous dysplasia, spondylitis tuberculosa, Paget's disease, hyperstosis frontalis interna, myositis, ossificans, and in rapidly growing epiphyses. The tendency for fluorine F 18 ions to accumulate in the vicinity of primary and metastatic malignancy in bone has proven clinically useful in detection of such lesions
Absorption
Following intravenous administration, Sodium Fluoride F 18 injection provides fluorine F 18 ions that rapidly equilibrate, primarily within the extracellular fluid space.
Route of Elimination
Fluorine F 18 ions are rapidly eliminated via the renal system. 20% or more of the fluorine F 18 ions are cleared from the body in the urine within the first 2 hours after intravenous administration.
Volume of Distribution
0.5-0.7 L/Kg
Clearance
Renal clearance for fluoride is 48-147 mL/min, depending upon urinary flow and pH.
First, the 18F- exchanges for an OH- ion on the surface of the hydroxyapatite matrix of bone and this is followed by migration of the 18F- into the crystalline matrix of the bone where it is retained until the bone is remodelled.
110 min.
18F-fluoride is a highly sensitive bone-seeking PET tracer used for detection of skeletal abnormalities. The uptake mechanism of 18F-fluoride has better pharmacokinetic characteristics (compared to other elements) including faster blood clearance and 2-fold higher uptake in bone. Uptake of 18F-fluoride reflects blood flow and bone remodeling.
Related Excipient Companies
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
